Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 10.71
- Piotroski Score 5.00
- Grade Buy
- Symbol (MDXG)
- Company MiMedx Group, Inc.
- Price $5.83
- Changes Percentage (3.19%)
- Change $0.18
- Day Low $5.70
- Day High $5.87
- Year High $9.27
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 10/28/2024
- Fiscal Year End N/A
- Average Stock Price Target $11.00
- High Stock Price Target $12.00
- Low Stock Price Target $8.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.52
- Trailing P/E Ratio 13.52
- Forward P/E Ratio 13.52
- P/E Growth 13.52
- Net Income $67.44 M
Income Statement
Quarterly
Annual
Latest News of MDXG
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
MiMedx Group (NASDAQ:MDXG) shareholders have endured a 56% loss from investing in the stock three years ago
Investing in stocks means some may perform poorly, like MiMedx Group, Inc. (NASDAQ:MDXG) down 56% in 3 years. Despite recent drops, revenue has grown 11% annually. Consider analyzing fundamental data ...
By Yahoo! Finance | 1 month ago -
With 45% ownership, MiMedx Group, Inc. (NASDAQ:MDXG) has piqued the interest of institutional investors
Analyzing analyst forecasts and ownership structure can help predict a company's future performance. Institutional investors hold 45% stake in MiMedx Group, with top shareholders being Essex Woodlands...
By Yahoo! Finance | 3 months ago
